BACKGROUND: Changes in endometrial cancer incidence rates after the precipitous decline in menopausal hormone therapy (MHT) use in 2002 have not been evaluated. METHODS: Using data from the Surveillance, Epidemiology, and End Results Program from 1992 to 2009 (SEER 13), we identified 63428 incident endometrial cancer cases among women ages 20-74. We compared annual percent change (APC) in endometrial cancer incidence rates from 1992 to 2002 to rates from 2003 to 2009. RESULTS: In contrast to the constant endometrial cancer rate pattern observed from 1992 to 2002 (APC 0.0%), rates increased after 2002 in women 50-74 years old (2.5%; PAPC comparison<0.01). Endometrial cancer incidence increased over the entire time period among women ages 20-49 (1992-2002: 1.1%; 2003-2009: 2.1%; PAPC comparison=0.21). Post-2002 increases in incidence among women ages 50-74 were specific to Type I endometrial tumors (1992-2002: -0.6%; 2003-2009: 1.6%; PAPC comparison<0.01). DISCUSSION: The increase in endometrial cancer incidence rates after 2002 may be related to the widespread decrease in estrogen plus progestin MHT use, which has been reported to lower endometrial cancer risk in overweight and obese women. Published by Elsevier Ltd.
BACKGROUND: Changes in endometrial cancer incidence rates after the precipitous decline in menopausal hormone therapy (MHT) use in 2002 have not been evaluated. METHODS: Using data from the Surveillance, Epidemiology, and End Results Program from 1992 to 2009 (SEER 13), we identified 63428 incident endometrial cancer cases among women ages 20-74. We compared annual percent change (APC) in endometrial cancer incidence rates from 1992 to 2002 to rates from 2003 to 2009. RESULTS: In contrast to the constant endometrial cancer rate pattern observed from 1992 to 2002 (APC 0.0%), rates increased after 2002 in women 50-74 years old (2.5%; PAPC comparison<0.01). Endometrial cancer incidence increased over the entire time period among women ages 20-49 (1992-2002: 1.1%; 2003-2009: 2.1%; PAPC comparison=0.21). Post-2002 increases in incidence among women ages 50-74 were specific to Type I endometrial tumors (1992-2002: -0.6%; 2003-2009: 1.6%; PAPC comparison<0.01). DISCUSSION: The increase in endometrial cancer incidence rates after 2002 may be related to the widespread decrease in estrogen plus progestin MHT use, which has been reported to lower endometrial cancer risk in overweight and obesewomen. Published by Elsevier Ltd.
Authors: Patricia M Jamison; Anne-Michelle Noone; Lynn A G Ries; Nancy C Lee; Brenda K Edwards Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-12-12 Impact factor: 4.254
Authors: Erika A Waters; Kathleen A Cronin; Barry I Graubard; Paul K Han; Andrew N Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-02 Impact factor: 4.254
Authors: Britton Trabert; Nicolas Wentzensen; Hannah P Yang; Mark E Sherman; Albert R Hollenbeck; Yikyung Park; Louise A Brinton Journal: Int J Cancer Date: 2012-08-30 Impact factor: 7.396
Authors: A Doll; M Abal; M Rigau; M Monge; M Gonzalez; S Demajo; E Colás; M Llauradó; H Alazzouzi; J Planagumá; M A Lohmann; J Garcia; S Castellvi; J Ramon y Cajal; A Gil-Moreno; J Xercavins; F Alameda; J Reventós Journal: J Steroid Biochem Mol Biol Date: 2007-09-15 Impact factor: 4.292
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Peter M Ravdin; Kathleen A Cronin; Nadia Howlader; Christine D Berg; Rowan T Chlebowski; Eric J Feuer; Brenda K Edwards; Donald A Berry Journal: N Engl J Med Date: 2007-04-19 Impact factor: 91.245
Authors: Michele L Cote; Tala Alhajj; Julie J Ruterbusch; Leslie Bernstein; Louise A Brinton; William J Blot; Chu Chen; Margery Gass; Sarah Gaussoin; Brian Henderson; Eunjung Lee; Pamela L Horn-Ross; Laurence N Kolonel; Andrew Kaunitz; Xiaolin Liang; Wanda K Nicholson; Amy B Park; Stacey Petruzella; Timothy R Rebbeck; V Wendy Setiawan; Lisa B Signorello; Michael S Simon; Noel S Weiss; Nicolas Wentzensen; Hannah P Yang; Anne Zeleniuch-Jacquotte; Sara H Olson Journal: Cancer Causes Control Date: 2014-12-23 Impact factor: 2.506
Authors: Megan A Clarke; Beverly J Long; Arena Del Mar Morillo; Marc Arbyn; Jamie N Bakkum-Gamez; Nicolas Wentzensen Journal: JAMA Intern Med Date: 2018-09-01 Impact factor: 21.873
Authors: Faina Linkov; Sharon L Goughnour; Shalkar Adambekov; Anna Lokshin; Joseph L Kelley; Paniti Sukumvanich; John T Comerci; Kacey G Marra; Lauren E Kokai; J Peter Rubin; Anda M Vlad; Brian J Philips; Robert P Edwards Journal: Biomark Med Date: 2018-07-25 Impact factor: 2.851
Authors: R T Chlebowski; G L Anderson; G E Sarto; R Haque; C D Runowicz; A K Aragaki; C A Thomson; B V Howard; J Wactawski-Wende; C Chen; T E Rohan; M S Simon; S D Reed; J E Manson Journal: J Natl Cancer Inst Date: 2015-12-14 Impact factor: 13.506
Authors: John K Chan; Stephanie Chow; Subasish Bhowmik; Amandeep Mann; Daniel S Kapp; Robert L Coleman Journal: Clin Exp Metastasis Date: 2018-06-21 Impact factor: 5.150
Authors: Maxine M Chen; Tracy A O'Mara; Deborah J Thompson; Jodie N Painter; John Attia; Amanda Black; Louise Brinton; Stephen Chanock; Chu Chen; Timothy Ht Cheng; Linda S Cook; Marta Crous-Bou; Jennifer Doherty; Christine M Friedenreich; Montserrat Garcia-Closas; Mia M Gaudet; Maggie Gorman; Christopher Haiman; Susan E Hankinson; Patricia Hartge; Brian E Henderson; Shirley Hodgson; Elizabeth G Holliday; Pamela L Horn-Ross; David J Hunter; Loic Le Marchand; Xiaolin Liang; Jolanta Lissowska; Jirong Long; Lingeng Lu; Anthony M Magliocco; Lynn Martin; Mark McEvoy; Sara H Olson; Irene Orlow; Loreall Pooler; Jennifer Prescott; Radhai Rastogi; Timothy R Rebbeck; Harvey Risch; Carlotta Sacerdote; Frederick Schumacher; Veronica Wendy Setiawan; Rodney J Scott; Xin Sheng; Xiao-Ou Shu; Constance Turman; David Van Den Berg; Zhaoming Wang; Noel S Weiss; Nicholas Wentzensen; Lucy Xia; Yong-Bing Xiang; Hannah P Yang; Herbert Yu; Wei Zheng; Paul D P Pharoah; Alison M Dunning; Ian Tomlinson; Douglas F Easton; Peter Kraft; Amanda B Spurdle; Immaculata De Vivo Journal: Hum Mol Genet Date: 2016-03-23 Impact factor: 6.150